- Home
- ASTL vs REPL Comparison
ASTL vs REPL Comparison
Compare ASTL & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTL
- REPL
- Stock Information
- Founded
- ASTL 1902
- REPL 2015
- Country
- ASTL Canada
- REPL United States
- Employees
- ASTL N/A
- REPL N/A
- Industry
- ASTL Steel/Iron Ore
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- ASTL Industrials
- REPL Health Care
- Exchange
- ASTL Nasdaq
- REPL Nasdaq
- Market Cap
- ASTL 733.5M
- REPL 757.8M
- IPO Year
- ASTL N/A
- REPL 2018
- Fundamental
- Price
- ASTL $6.63
- REPL $12.13
- Analyst Decision
- ASTL
- REPL Strong Buy
- Analyst Count
- ASTL 0
- REPL 7
- Target Price
- ASTL N/A
- REPL $20.83
- AVG Volume (30 Days)
- ASTL 944.0K
- REPL 1.5M
- Earning Date
- ASTL 07-22-2025
- REPL 08-07-2025
- Dividend Yield
- ASTL 2.94%
- REPL N/A
- EPS Growth
- ASTL N/A
- REPL N/A
- EPS
- ASTL N/A
- REPL N/A
- Revenue
- ASTL $1,635,857,227.00
- REPL N/A
- Revenue This Year
- ASTL $0.95
- REPL N/A
- Revenue Next Year
- ASTL $21.63
- REPL N/A
- P/E Ratio
- ASTL N/A
- REPL N/A
- Revenue Growth
- ASTL N/A
- REPL N/A
- 52 Week Low
- ASTL $4.17
- REPL $6.44
- 52 Week High
- ASTL $12.14
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- ASTL 51.03
- REPL 69.61
- Support Level
- ASTL $6.88
- REPL $9.26
- Resistance Level
- ASTL $7.14
- REPL $9.90
- Average True Range (ATR)
- ASTL 0.27
- REPL 0.57
- MACD
- ASTL -0.07
- REPL 0.19
- Stochastic Oscillator
- ASTL 28.07
- REPL 88.68
About ASTL Algoma Steel Group Inc.
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.